A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
for Lupus Nephritis
11 locations incl. Loma Linda
Sponsor: Hoffmann-La Roche
Sex: All·Age: 5 - 17
Code: NCT05039619·Phase 2·Recruiting